Price
$114.66+32.28%Social Signal Score
Analyst Ratings
30 analystsRevenue
$728.90M+28.61%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Prahlad R. Singh
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 11,000
- Beta
- 1.08
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 3.65
Financials
Revenue
$728.90M+28.6%Net Income
$62.30M-3.9%EBITDA
$201.41M+91.1%Free Cash Flow
$152.36M+7.7%EPS (diluted)
$0.56-4.9%Shares Outstanding (diluted)
111.83M+1.5%Operating Expenses
$323.44MCash & Debt
$592.80MReturn of Capital
$7.91MRevenue by Segment (annual)
$2.86BDividend per Share
$0.07Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.86B | $241.68M | $2.08 |
| 2024 | $2.76B | $295.83M | $2.41 |
| 2023 | $2.75B | $-118.38M | $-0.95 |
| 2022 | $3.31B | $569.18M | $4.51 |
| 2021 | $3.83B | $943.16M | $8.12 |
| 2020 | $3.78B | $728.10M | $6.53 |
| 2019 | $2.88B | $227.56M | $2.05 |
| 2018 | $2.78B | $238.79M | $2.16 |
| 2017 | $2.26B | $113.02M | $1.03 |
| 2016 | $2.12B | $233.68M | $2.13 |
| 2015 | $2.10B | $212.45M | $1.89 |
| 2014 | $2.24B | $158.04M | $1.40 |
| 2013 | $2.17B | $167.92M | $1.50 |
| 2012 | $2.12B | $68.44M | $0.60 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from RVTY's reported EPS growth of 10.0% a year over 13 years.
- EPS in 5 years
- $3.44
- Implied price
- $161.58
- Return from $146.98
- 1.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $80.33 — -45.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 33 | 40 | 47 | 54 | 61 |
|---|---|---|---|---|---|
| 0.0% | -13.7% | -10.3% | -7.4% | -4.7% | -2.4% |
| 5.0% | -9.4% | -5.8% | -2.7% | 0.0% | 2.5% |
| 10.0% | -5.0% | -1.3% | 1.9% | 4.8% | 7.4% |
| 15.0% | -0.7% | 3.2% | 6.5% | 9.5% | 12.2% |
| 20.0% | 3.6% | 7.6% | 11.2% | 14.3% | 17.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
85+13.33%Social Signal Score
Mentions (36)
- News (RSS)seekingalpha·4d ago·Neutral
Revvity, Inc. (RVTY) Analyst/Investor Day - Slideshow
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Revvity, Inc. (RVTY) Presents at Jefferies Global Healthcare Conference 2026 Transcript Revvity, Inc. (RVTY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - News (RSS)zerohedge·9d ago·Neutral
… October PPI (8:30am). Fed speaker slate includes Goolsbee (8:30am), Collins (9:10am and 10:35am), Logan (9:40am), Bowman (10:50am), Daly (12pm) and Jefferson (7pm). Revvity hosts an investor day, JPMorgan holds its US opportunities forum in Miami, and Anthropic livestreams an investor event with Dario Amodei and Jamie Dimon.Market SnapshotTop Overnight NewsPresident Trump said the US doesn't need a deal with Iran, helping Brent add 3.3% on Thursday to about $96: BBGUkraine's Zelenskyy hailed pr…
View source ↗ - Newszacks.com·16d ago·Positive
All You Need to Know About Revvity (RVTY) Rating Upgrade to Buy Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsmarketbeat.com·18d ago·Positive
Revvity Q3 Earnings Call Highlights Revvity NYSE: RVTY reported third-quarter results that exceeded its expectations, supported by stronger demand in its Life Sciences segment, continued growth in Diagnostics and expanding interest in artificial intelligence-related research tools.
View source ↗ - News (RSS)businessinsider·19d ago·Neutral
Revvity rises on full-year guidance boost
View source ↗ - News (RSS)zerohedge·19d ago·Neutral
… quarterly outlook that pointed to a potential slowdown in sales growth, with revenue expected to be roughly $2.65 billion in the three months ended Dec. 31.Revvity (RVTY) jumps 7% after the life sciences company boosted its outlook for organic revenue growth and adjusted profit for the full year, following third-quarter results that were better than expectations.Shopify (SHOP) slumps 16% after the e-commerce firm reported subscription revenue for the third quarter that fell short of the average…
View source ↗ - Newszacks.com·19d ago·Positive
RVTY Q3 Earnings Beat Estimates on Life Sciences Strength, '26 View Up Revvity's Q3 2026 earnings and revenues beat estimates, fueled by Life Sciences growth and margin expansion, prompting an upward revision to its annual outlook.
View source ↗ - News (RSS)investing·19d ago·Neutral
Why is Revvity stock surging today?
View source ↗ - Newsbusinesswire.com·19d ago·Negative
Revvity Announces Financial Results for the Third Quarter of 2026 WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended October 4, 2026. The Company reported GAAP earnings per share from continuing operations of $0.56, as compared to $0.41 in the same period a year ago. Revenue for the quarter was $729 million, as compared to $699 million in the same period a year ago. GAAP operating income from continuing operations for the qua…
View source ↗ - News (RSS)investing·23d ago·Neutral
Revvity declares $0.07 quarterly dividend per share
View source ↗ - Newszacks.com·23d ago·Positive
Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock? RVTY's Q3 earnings may gain from recovering pharma demand, stronger HCS demand and software growth, despite lingering spending and TB-related headwinds.
View source ↗ - Newszacks.com·26d ago·Neutral
Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report? Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - Newszacks.com·26d ago·Neutral
Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newszacks.com·30d ago·Neutral
ELV vs. RVTY: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or Revvity (RVTY). But which of these two stocks offers value investors a better bang for their buck right now?
View source ↗ - Newszacks.com·31d ago·Neutral
Revvity Launches Signals LabGistics to Coordinate Scientific Workflows RVTY's AI-first Signals LabGistics aims to streamline scientific workflows, enhance R&D-to-manufacturing coordination and expand software growth opportunities.
View source ↗ - Newsseekingalpha.com·31d ago·Neutral
Revvity: A Diagnostics Annuity Is Quietly Funding An AI Data Engine Revvity is transforming from a legacy tools company into a diagnostics-driven, AI-enabled platform with robust double-digit diagnostics growth. The Diagnostics segment organic revenue rose 11%, while software ARR grew in the mid-20% range, offsetting Life Sciences weakness and China exit headwinds. Operating leverage is strong, with 13% EPS growth on 3% organic revenue growth and free cash flow conversion exceeding 100%, support…
View source ↗ - Newszacks.com·51d ago·Positive
Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock? Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsbusinesswire.com·51d ago·Neutral
Revvity to Hold Earnings Call on November 3, 2026 WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio web…
View source ↗ - Newszacks.com·54d ago·Neutral
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.
View source ↗ - Newszacks.com·58d ago·Neutral
RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.
View source ↗ - Newszacks.com·67d ago·Neutral
Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength? Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·69d ago·Positive
Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·72d ago·Negative
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
View source ↗ - Newszacks.com·73d ago·Positive
Why Revvity (RVTY) is a Top Momentum Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newsseekingalpha.com·74d ago·Neutral
Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
View source ↗ - Newsbusinesswire.com·74d ago·Negative
…y to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery WALTHAM, Mass.--(BUSINESS WIRE)-- #AI--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD's human pancreatic beta cell models …
View source ↗ - Newszacks.com·79d ago·Positive
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich? Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
View source ↗ - Newszacks.com·82d ago·Positive
What Makes Revvity (RVTY) a New Buy Stock Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newszacks.com·90d ago·Negative
Is the Options Market Predicting a Spike in Revvity Stock? Investors need to pay close attention to RVTY stock based on the movements in the options market lately.
View source ↗ - Newszacks.com·101d ago·Neutral
Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs RVTY launches SuperFlex, a compact automated prenatal screening system aimed at expanding rapid in-house testing for smaller labs and clinics.
View source ↗ - Newsbusinesswire.com·103d ago·Neutral
Revvity to Present at Upcoming Investor Conferences WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Wednesday, September 9, 2026 8:45 a.m. ET - Prahlad Singh, president and chief executive officer Morgan Stanley 24th Annual Global Healthcare Conference Monday, September 14, 2026 8:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Baird's 20
View source ↗ - Newsbusinesswire.com·104d ago·Neutral
Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the launch of the SuperFlex™ prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed to bring high-quality screening to laboratories and clinics seeking reliable, rapid solutions that fit lower-volume workflows. The system supports testing for preeclampsia, a condition that affects between 2% and 8% of pregna
View source ↗ - Newsmarketbeat.com·105d ago·Negative
Revvity Q2 Earnings Call Highlights Revvity NYSE: RVTY reported second-quarter results above its expectations and raised its full-year outlook, citing continued strength in diagnostics, improving demand from pharmaceutical and biotechnology customers, and growing orders tied to artificial intelligence-enabled drug discovery workflows.
View source ↗
Earnings
Mon, Feb 1(in 2 months)
Consensus estimate $1.61 per share
Typical surprise +5.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$1.38 vs $1.30beat
- Tue, Aug 4$1.41 vs $1.21beat
- Tue, May 5$1.06 vs $1.02beat
- Mon, Feb 2$1.70 vs $1.57beat
- Mon, Oct 27$1.18 vs $1.14beat
- Mon, Jul 28$1.18 vs $1.14beat
Estimates and results for RVTY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RVTY officers and directors.
- Bought
- —
- Sold
- $6.1m
0 trades
19 trades
- Gonzales Anitasold
- Krakowiak Maxwellsold
- Vohra Tajinder Ssold
- Gonzales Anitasold
- Gonzales Anitasold
- Victor Miriamesold
- Mcmurry-heath Michellesold
- Singh Prahlad R.sold
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Nov 10, 2026 (14d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (27d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Oct 12, 2026 (39d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Oct 12, 2026 (38d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Oct 12, 2026 (33d later)Sell$15,001 - $50,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 9, 2026 (36d later)Buy$15,001 - $50,000
- Gilbert Cisneroshouse · CA31 · disclosed May 11, 2026 (10d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Oct 10, 2025 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Sep 12, 2025 (30d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Aug 15, 2025 (23d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (22d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jul 11, 2025 (30d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 9, 2025 (12d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Buy$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Mar 21, 2025 (21d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
